The Wylder & Oakley Foundation was created after our twin boys, Wylder and Oakley, were diagnosed with ABCA3 deficiency, a rare genetic lung disease that affects the lungs’ ability to function properly.

Children born with ABCA3 often face severe breathing challenges and limited or no treatment options. In many cases, the only long-term option is lung transplantation, and tragically, some children do not survive.

But today, we have a breath of hope.

Researchers are working toward a gene therapy that could potentially correct the underlying genetic defect responsible for this disease. Early scientific research has shown promising results, but significant funding is needed to move this work forward.

Our foundation was created with one goal:

To accelerate the development of a gene therapy for ABCA3 and help bring this potential cure to children who need it most.

Every donation helps support the scientific research required to move this therapy closer to clinical trials and ultimately to the children and families who are waiting for it.

Together, we can help turn groundbreaking science into a life-saving treatment — and give children born with ABCA3 a future filled with healthy breaths.